Antibe Therapeutics Inc(Pre-Merger) ATBPF

Healthcare

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.

GREY:ATBPF - Post by User

Antibe Therapeutics Inc(Pre-Merger) > Pumpers don't get holidays....so expect Clown here all summe

<< Previous

Bullboard Posts

Next >>

Comment by nobeardon May 31, 2022 9:46pm

159 Views

Post# 34721991

RE:RE:RE:Pumpers don't get holidays....so expect Clown here all summe

Seems like Chinachin, stutters and stockings are all the same person verbally attacking one person. I don't know what it takes for the moderators to put this person in the penalty box. Ate question to ponder:. If long term pain medication is being resolved would not the royality payments be back on the table with the Chinese company?